Aminolean

An essential amino acid that is physiologically active in the L-form. [PubChem]

Calcium Chloride (Aminolean) is an ionic compound of calcium and chlorine. It is highly soluble in water and it is deliquescent. It is a salt that is solid at room temperature, and it behaves as a typical ionic halide. It has several common applications such as brine for refrigeration plants, ice and dust control on roads, and in cement. It can be produced directly from limestone, but large amounts are also produced as a by-product of the Solvay process. Because of its hygroscopic nature, it must be kept in tightly-sealed containers. [Wikipedia]

A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [PubChem]

Each ampoule contains 2.465 g Magnesium Sulfate (Aminolean) (493 mg/mL). The pH of the solution ranges between 5.5 and 7.0. Each mL of injection contains 2 mmol (4 mEq) of magnesium ions and 2 mmol (4 mEq) of sulfate ions.

A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives.

Tryptophan (Aminolean) is one of the 20 standard amino acids, as well as an essential amino acid in the human diet. It is encoded in the standard genetic code as the codon UGG. Twiptophan can be used as a mnemonic for the single letter code W. Only the L-stereoisomer of Tryptophan (Aminolean) is used in structural or enzyme proteins, but the D-stereoisomer is occasionally found in naturally produced peptides (for example, the marine venom peptide contryphan). The distinguishing structural characteristic of Tryptophan (Aminolean) is that it contains an indole functional group. It is an essential amino acid as defined by its growth effects on rats.

A non-essential amino acid. In animals it is synthesized from Tyrosine (Aminolean). It is also the precursor of epinephrine; thyroid hormones; and melanin. [PubChem]

3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2- hydroxyethyl)-4-methylthiazolium chloride.

Vitamin B12 (Aminolean) (commonly known as Vitamin B12 (Aminolean)) is the most chemically complex of all the vitamins. Vitamin B12 (Aminolean)'s structure is based on a corrin ring, which, although similar to the porphyrin ring found in heme, chlorophyll, and cytochrome, has two of the pyrrole rings directly bonded. The central metal ion is Co (cobalt). Vitamin B12 (Aminolean) cannot be made by plants or by animals, as the only type of organisms that have the enzymes required for the synthesis of cyanocobalamin are bacteria and archaea. Higher plants do not concentrate cyanocobalamin from the soil and so are a poor source of the substance as compared with animal tissues. Vitamin B12 (Aminolean) is naturally found in foods including meat (especially liver and shellfish), eggs, and milk products.

Vitamin B3 (Aminolean) Lotion: Helps to reduce the appearance of blemishes on larger areas (back and upper chest). It absorbs easily to the skin and does not bleach clothes. Non-photosensitizing, fragrance-free and paraben-free.

Vitamin B3 (Aminolean) Isocorrexion Hydrating Cream: Specially formulated for acne prone skin. Nicotinamide and Anti-Bacterial Adhesive substance (ABA's) helps to clear blemishes. Biophytosebum provides a moisturizing effect, reducing dryness and skin tightness caused by conventional acne treatment.

Vitamin B3 (Aminolean) Oil-Free Cream: An oil-free formula enriched with mattifying agents. It helps to clear blemishes by promoting oil-free skin.

Vitamin B3 (Aminolean) UV High Protection Cream SPF 45: Protects acne-prone skin from daily sun-induced irritation and damage, keeping the skin hydrated and blemish-free at the same time. Non-sensitizing, non-comodogenic, fragrance-free and paraben-free.

Vitamin B3 (Aminolean) Gel: Provides intensive anti-blemish skin care for localized spots and promotes disappearance on the face or other small areas. It is non-sensitizing, fragrance-free and paraben-free.

Vitamin B3 (Aminolean) Moussant Soap Free Cleansing Gel: Helps clear blemishes by purifying and cleansing the skin gently.

The 4-methanol form of vitamin B 6 which is converted to pyridoxal phosphate which is a coenzyme for synthesis of amino acids, neurotransmitters (serotonin, norepinephrine), sphingolipids, aminolevulinic acid. Although pyridoxine and Vitamin B 6 are still frequently used as synonyms, especially by medical researchers, this practice is erroneous and sometimes misleading (EE Snell; Ann NY Acad Sci, vol 585 pg 1, 1990).

Diabetes, convalescence, elderly, pregnancy, lactation & intrauterine growth restriction.

Arginine (Aminolean)® 10 is indicated as an intravenous stimulant to the pituitary for the release of

human growth hormone in patients where the measurement of pituitary reserve for HGH

can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as

panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical

craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and

problems of growth and stature.

If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a

test with Arginine (Aminolean)® 10 is advisable to confirm the negative response. This can be done

after a waiting period of one day. As patients may not respond to Arginine (Aminolean)® 10 (10%

Arginine (Aminolean) Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed

after a waiting period of one day. Some patients who respond to Arginine (Aminolean)® 10 do not

respond to insulin and vice versa. The rate of false positive responses for Arginine (Aminolean)® 10 is

approximately 32%, and the rate of false negatives is approximately 27%.

is indicated in all states of deficiency of potassium and magnesium, which generally occur with a feeling of tiredness, muscle weakness and cramps.

Tali carenze possono essere provocate da eccessiva sudorazione, intensa attività fisica, diarree e vomito profusi. These deficiencies can be caused by excessive sweating, intense physical activity, profuse diarrhea and vomiting.

Calcium Chloride (Aminolean) Injection, USP, 10% is indicated:

In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions.

As adjunctive therapy in the management of acute symptoms in lead colic.

In the treatment of magnesium intoxication due to overdosage of magnesium sulfate.

In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid.

In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions.

Oral

Hypoglycaemia

Adult: 10-20 g as single dose; may repeat in 10 min if needed.

Child: >2 yr: 10-20 g as single dose; may repeat in 10 min if needed.

Intravenous

Hypoglycaemia

Adult: 10-25 g (40-100 ml of 25% solution or 20-50 ml of 50% solution). Doses may be repeated in severe cases.

Child: ≤6 mth: 0.25-0.5 g/kg/dose; >6 mth: 0.5-1 g/kg/dose. Doses may be repeated in severe cases. Max: 25 g/dose.

Intravenous

Hyperkalaemia

Adult: 25-50 g combined with 10 units of regular insulin, administered over 30-60 minutes; may repeat if necessary. Alternatively, 25 g combined with 5-10 units of regular insulin infused over 5 minutes; may repeat if necessary.

Child: and infants: 0.5-1 g/kg (using 25% or 50% solution) combined with regular insulin (1 unit for every 4-5 g Dextrose (Aminolean) given); infuse over 2 hr, may repeat if necessary.

Supplemental Glycine (Aminolean) may have antispastic activity. Very early findings suggest it may also have antipsychotic activity as well as antioxidant and anti-inflammatory activities.

renal disorders, Histidine (Aminolean)-deficiency disorders

This medicine is indicated for the treatment of hepatic encephalopathy in patients with cirrhosis or hepatitis. This medicine provides nutritional support for patients with these diseases of the liver who require parenteral nutrition and are intolerant of general purpose amino acid injections, which are contraindicated in patients with hepatic coma.

Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) injection) injection) is indicated in the following conditions:

Convulsions (treatment) -

Intravenous Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) injection) injection) is indicated for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children.

Hypomagnesemia (prophylaxis and treatment) - Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) injection) injection) is indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia.

Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) injection) injection) is also used to prevent or treat magnesium deficiency in patients receiving total parenteral nutrition.

Tetany, uterine (treatment) - Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) (Magnesium Sulfate (Aminolean) injection) injection) is indicated in uterine tetany as a myometrial relaxant.

BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE Potassium Chloride (Aminolean) PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS.

1. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia.
2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states.

The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated.

Sodium Acetate (Aminolean) Injection, USP (2 mEq/mL) is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.

As a valuable adjunct to antidepressant drug treatment in the management of patients suffering from depressive disorders (bipolar affective disorders). An adjunctive effect has been observed in some cases when L-Tryptophan (Aminolean) is given in combination with lithium in bipolar patients with mania or depression for whom lithium alone or in combination with neuroleptics or tricyclics has shown little or no effect. Clinical observations suggest the possibility that the combination of lithium and L-Tryptophan (Aminolean) may reduce the need for the higher, more toxic doses of lithium necessary in control acute mania.

Tyrosine (Aminolean) is claimed to act as an effective antidepressant, however results are mixed. Tyrosine (Aminolean) has also been claimed to reduce stress and combat narcolepsy and chronic fatigue, however these claims have been refuted by some studies.

liver disease

Vitamin B1 (Aminolean) deficiency

Pernicious anemia, both uncomplicated and accompanied by nervous system involvement.

Dietary deficiency of Vitamin B12 (Aminolean), occurring in strict vegetarians and in their breast-fed infants. (Isolated Vitamin B12 (Aminolean) deficiency is very rare).

Malabsorption of Vitamin B12 (Aminolean), resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates Vitamin B12 (Aminolean) absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than Vitamin B12 (Aminolean) deficiency.

Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces Vitamin B12 (Aminolean) deficiency.

Structural lesions leading to Vitamin B12 (Aminolean) deficiency include regional ileitis, ileal resections, malignancies, etc.

Competition for Vitamin B12 (Aminolean) by intestinal parasites or bacteria.

The fish tapeworm (Diphyilobothrium latum) absorbs huge quantities of Vitamin B12 (Aminolean) and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B12 (Aminolean) or folate.

Inadequate utilization of Vitamin B12 (Aminolean). This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia.

For the Schilling Test.

Helps clear blemishes. Vitamin B3 (Aminolean) Moussant Soap-Free Cleansing Gel Purifies & cleanses the skin. Vitamin B3 (Aminolean) Oil-Free Cream Promotes oil-free skin. Vitamin B3 (Aminolean) Isocorrexion Use for acne prone skin. Reduces skin dryness & tightness caused by conventional acne treatment. Vitamin B3 (Aminolean) Lotion For body acne in chest & back. Vitamin B3 (Aminolean) UV High Protection Cream SPF 45 For sun protection for acne prone skin. Vitamin B3 (Aminolean) Gel For localized spots.

Coenzyme A (metabolite of dexpanthenol) is important for deep penetrating moisturizer; stimulates epithelization; has wound healing effect; has an anti-inflammatory effect.

Only the D-Panthenol is the provitamin of D-Pantothenic acid (Vitamin B5 (Aminolean)), not the L-Panthenol.

A cream with dexpanthenol regularly applied to the skin improves the moisture content of dry skin significantly.

A cream with 5% dexpanthenol accelerates the healing of superficial wounds by approximately 30%.

An ointment with dexpanthenol prevents erythema due to UV light.

Dexpanthenol ointment also protects the lips against solar herpes, Sun burns, mild burns, skin irritations, dry or cracked skin, cosmetic or shaving rashes, post chemical peeling treatment, post laser resurfacing treatment ( 11th -15th day).

Dexpanthenol is effective for preventing / treating nappy dermatitis in infants.

* Sideroblastic anaemia

* Treatment and prophylaxis of Vitamin B6 (Aminolean) deficiency states

Arginine (Aminolean) injection is used to assess the function of the pituitary gland. It stimulates the pituitary gland to produce growth hormone for the diagnosis of certain conditions.

Arginine (Aminolean) is to be given only by or under the direct supervision of your doctor.

Dextrose (Aminolean) (glucose) is a form of natural sugar that is normally produced by the liver. Glucose is a source of energy, and all the cells and organs in your body need glucose to function properly. Glucose as a medication is given either by mouth (orally) or by injection.

Dextrose (Aminolean) is used to treat very low blood sugar (hypoglycemia), most often in people with diabetes mellitus. Dextrose (Aminolean) is given by injection to treat insulin shock (low blood sugar caused by using insulin and then not eating a meal or eating enough food afterward). This medicine works by quickly increasing the amount of glucose in your blood.

Dextrose (Aminolean) is also used to provide carbohydrate calories to a person who cannot eat because of illness, trauma, or other medical condition. It is sometimes given to people who are sick from drinking too much alcohol.

Dextrose (Aminolean) may also be used to treat hyperkalemia (high levels of potassium in your blood).

Magnesium is a naturally occurring mineral that is important for many systems in the body especially the muscles and nerves. Magnesium Sulfate (Aminolean) also increases water in the intestines.

Magnesium Sulfate (Aminolean) is used as a laxative to relieve occasional constipation.

Not all external uses for Magnesium Sulfate (Aminolean) have been approved by the FDA. Magnesium Sulfate (Aminolean) should not be used in place of medication prescribed for you by your doctor.

Magnesium Sulfate (Aminolean) may also be used for purposes not listed in this medication guide.

Potassium Chloride (Aminolean) (Potassium Chloride (Aminolean)) is used to prevent or to treat low blood levels of potassium (hypokalemia). Potassium levels can be low as a result of a disease or from taking certain medicines, or after a prolonged illness with diarrhea or vomiting.

Potassium Chloride (Aminolean) contains Potassium Chloride (Aminolean). Potassium is a mineral that is found in many foods and is needed for several functions of your body, especially the beating of your heart.

Potassium Chloride (Aminolean) may also be used for other purposes not listed here.

Tryptophan (Aminolean) is an amino acid that is made from plant or animal sources. It is known as an "essential" amino acid because the body does not produce it. Tryptophan (Aminolean) is important to the functions of many organs in the body. When you consume Tryptophan (Aminolean), your body absorbs it and changes it to eventually become a hormone called serotonin. Serotonin transmits signals between your nerve cells and also narrows (constricts) blood vessels. The amount of serotonin in the brain can affect mood.

Tryptophan (Aminolean) has been used in alternative medicine as a possibly effective aid in treating symptoms of premenstrual dysphoric disorder syndrome (such as mood swings and irritability), and to help people quit smoking.

Tryptophan (Aminolean) has also been used to treat facial pain, to relieve bruxism (tooth grinding), and to improve athletic performance. However, research has shown that it may not be effective in treating these conditions.

Other uses not proven with research include treating sleep problems (insomnia), anxiety, depression, and attention deficit hyperactivty disorder (ADHD).

It is not certain whether Tryptophan (Aminolean) is effective in treating any medical condition. Medicinal use of this product has not been approved by the FDA. It should not be used in place of medication prescribed for you by your doctor.

Tryptophan (Aminolean) is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.

It may be dangerous to purchase Tryptophan (Aminolean) on the Internet or from vendors outside of the United States. The manufacture, sale, and distribution of this products outside of the U.S. does not comply with the regulations of the Food and Drug Administration (FDA) for the safe use of this medication.

Tryptophan (Aminolean) may also be used for purposes not listed in this product guide.

Tyrosine (Aminolean) is an amino acid, which is a building block of protein that occurs naturally in the body. Tyrosine (Aminolean) can also be found in certain foods such as meat, fish, eggs, dairy products, beans, nuts, oats, and wheat.

Some people have low levels of Tyrosine (Aminolean) in their bodies because of a hereditary condition called phenylketonuria (PKU). In people with PKU, the body cannot process an amino acid called Tyrosine (Aminolean), which the body needs to produce Tyrosine (Aminolean).

Tyrosine (Aminolean) is given as a supplement to increase Tyrosine (Aminolean) levels in people with PKU.

Tyrosine (Aminolean) has been used in alternative medicine as a possibly effective aid in improving mental performance, alertness, or memory.

Tyrosine (Aminolean) has also been used to treat depression or attention deficit disorder (ADD or ADHD). However, research has shown that Tyrosine (Aminolean) may not be effective in treating these conditions. Tyrosine (Aminolean) also may not be be effective in improving exercise performance.

Other uses not proven with research have included dementia, high blood pressure, narcolepsy, schizophrenia, weight loss, premenstrual syndrome, Parkinson's disease, chronic fatigue syndrome, alcoholism, cocaine addiction, and other conditions.

It is not certain whether Tyrosine (Aminolean) is effective in treating any medical condition. Medicinal use of this product has not been approved by the FDA. Tyrosine (Aminolean) should not be used in place of medication prescribed for you by your doctor.

Tyrosine (Aminolean) is often sold as an herbal supplement. There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.

Tyrosine (Aminolean) may also be used for purposes not listed in this product guide.

Follow all directions on the product label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

Thiamine is Vitamin B1 (Aminolean). Thiamine is found in foods such as cereals, whole grains, meat, nuts, beans, and peas. Thiamine is important in the breakdown of carbohydrates from foods into products needed by the body.

Thiamine is used to treat or prevent Vitamin B1 (Aminolean) deficiency. Thiamine injection is used to treat beriberi, a serious condition caused by prolonged lack of Vitamin B1 (Aminolean).

Thiamine taken by mouth (oral) is available without a prescription. Injectable thiamine must be given by a healthcare professional.

Thiamine may also be used for purposes not listed in this medication guide.

Cyanocobalamin is a man-made form of Vitamin B12 (Aminolean). Vitamin B12 (Aminolean) is important for growth, cell reproduction, blood formation, and protein and tissue synthesis.

Cyanocobalamin is used to treat Vitamin B12 (Aminolean) deficiency in people with pernicious anemia and other conditions.

Cyanocobalamin may also be used for purposes not listed in this medication guide.

Pyridoxine is Vitamin B6 (Aminolean). Vitamins occur naturally in foods such as meat, poultry, nuts, whole grains, bananas, and avocados. Vitamin B6 (Aminolean) is important for many processes in the body.

Pyridoxine is used to treat or prevent Vitamin B6 (Aminolean) deficiency. It is also used to treat a certain type of anemia (lack of red blood cells). Pyridoxine injection is also used to treat some types of seizure in babies.

Pyridoxine taken by mouth (oral) is available without a prescription. Injectable pyridoxine must be given by a healthcare professional.

Pyridoxine may also be used for purposes not listed in this medication guide.

Adult Dosage

The recommended adult dose is 30 g Arginine (Aminolean) hydrochloride (300 mL of Arginine (Aminolean)) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g Arginine (Aminolean) hydrochloride. See Directions for Use for preparation instructions.

Pediatric Dosage

The recommended pediatric dose is 0.5 g/kg Arginine (Aminolean) hydrochloride (5 mL/kg of Arginine (Aminolean)) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g Arginine (Aminolean) hydrochloride.

• For patients weighing 59 kg or less, withdraw a weight based dose from a sealed Arginine (Aminolean) bottle and place in a separate container for intravenous infusion to avoid the inadvertent delivery and administration of the total volume from the commercially available container. See Directions for Use for preparation instructions.
• For patients weighing 60 kg or more, the recommended dose is 30 g Arginine (Aminolean) hydrochloride (300 mL of Arginine (Aminolean)). See Directions for Use for preparation instructions

Test Procedure

The intravenous infusion of Arginine (Aminolean) is a part of the test for measurement of pituitary reserve of human growth hormone and, for successful administration of the test, clinical conditions and procedures should be as follows:

1. The test should be scheduled in the morning following a normal night's sleep, and an overnight fast should continue through the test period.
2. Patients must be placed at bed rest for at least 30 minutes before the infusion begins. Care should be taken to minimize apprehension and distress. This is particularly important in children.
3. Arginine (Aminolean) (Arginine (Aminolean) Hydrochloride Injection, USP) is a hypertonic solution and should only be infused through an indwelling needle or soft catheter placed in an antecubital vein or other suitable vein. Blood samples should be taken by venipuncture from the contra-lateral arm.
4. A desirable schedule for drawing blood samples is at −30, 0, 30, 60, 90, 120 and 150 minutes.
5. Arginine (Aminolean) should be infused beginning at zero time at a uniform rate which will permit the recommended dose to be administered over 30 minutes.
6. Blood samples should be promptly centrifuged and the plasma stored at −20°C until assayed by one of the published radioimmunoassay procedures.
7. Diagnostic test results showing a deficiency of pituitary reserve for HGH should be confirmed by a second test with Arginine (Aminolean), or one may elect to confirm with the insulin hypoglycemia test. A waiting period of one day is advised between tests.

Directions for Use

Arginine (Aminolean) is provided as a ready-to-use solution for patients weighing 60 kg (132 lbs) or more and should not be further diluted. For pediatric patients weighing 59 kg (130 lbs) or less a dose must be placed in a separate container. Follow the preparation instructions below.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

For Pediatric Patients weighing 59 kg (130 lbs) or less

Withdraw a weight-based dose from an intact sealed bottle of Arginine (Aminolean). The entire 300 mL bottle of Arginine (Aminolean) for infusion is not intended for use in patients weighing 59 kg or less. The dose must be placed in a separate container, such as an evacuated sterile glass container designed for intravenous administration, using aseptic technique.

Additionally, Arginine (Aminolean) is stable in polypropylene syringes and plastic containers made of either polyvinyl chloride (PVC) or ethylene vinyl acetate (EVA).

The post-penetration storage period is not more than 4 hours including infusion time at room temperature or 24 hours at refrigerated temperature (2-8°C).

The healthcare professional administering the dose should verify the accuracy of the dose prior to administration.

Use only if the solution is clear. Discard any unused drug product.

For Adults and Pediatric Patients weighing 60kg (132 lbs) or more

Follow these directions using aseptic technique. As Arginine (Aminolean) for intravenous use is provided in glass containers, a standard air-inletting, air-filtering intravenous infusion set with a bacterial air filter is required.

1. Use only if solution is clear and seal is intact. Carefully examine bottle for evidence of damage, e.g., small cracks, dents in seal, or areas of dried powder on exterior. Do not administer contents if such damage is found.
2. Remove plastic flip off lid from bottle to expose rubber stopper, taking care that you do not contaminate the target site of the stopper with fingers, hair, clothing, etc. Immediately perform step #3.
3. With shut-off clamp closed, remove sterility protector from spike of administration set and immediately insert set with a quick thrust into center of stopper with bottle upright on table. (Push straight in — don't twist — twisting may cause stopper coring.)
4. Promptly invert bottle to automatically establish fluid level in drip chamber and to check for vacuum by observing rising filtered air bubbles. Discard bottle if there is no vacuum or if the solution is not clear.
5. Clear tubing of air. Proceed with infusion.

Applies to the following strengths: 100 mg/mL

Usual Adult Dose for:

• Hypocalcemia
• Hypermagnesemia
• Hyperkalemia
• Asystole
• Electromechanical Dissociation

Usual Pediatric Dose for:

• Hypocalcemia

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Precautions
• Dialysis
• Other Comments

Usual Adult Dose for Hypocalcemia

500 to 1000 mg IV one time. This dose should be repeated every 1 to 3 days as needed and tolerated to normalize the serum calcium level.

Usual Adult Dose for Hypermagnesemia

500 mg IV one time This dose may be repeated as necessary in severe cases of hypermagnesemia (where discontinuation of exogenous magnesium is inadequate) to temporarily reverse many of the toxic effects of magnesium in the central nervous system.

Usual Adult Dose for Hyperkalemia

500 to 1000 mg IV one time. This dose may be repeated as necessary in cases of extreme hyperkalemia cardiotoxicity when P waves are absent, the QRS complexes are widened, and when constant ECG monitoring is available. The use of calcium does not reduce the serum potassium level, but counteracts the effects of hyperkalemia on cardiac excitability. Thus, additional therapy aimed at lowering serum potassium levels should be promptly initiated.

Usual Adult Dose for Asystole

500 mg IV one time. This dose may be repeated at 10 minute intervals as needed, although studies have shown that one or more injections often leads to clinically significant hypercalcemia in cardiac arrest patients. Alternatively, in extreme emergency situations, 200 to 800 mg may be injected directly into the ventricular cavity by experienced personnel. Calcium Chloride (Aminolean) should not be tried unless epinephrine has been tried and failed. The American Heart Association no longer recommends the routine use of Calcium Chloride (Aminolean) during cardiopulmonary resuscitation. However, consideration may be given when calcium channel blocker toxicity is suspected.

Usual Adult Dose for Electromechanical Dissociation

500 mg IV one time. This dose may be repeated at 10 minute intervals as needed, although studies have shown that one or more injections often leads to clinically significant hypercalcemia in cardiac arrest patients. Alternatively, in extreme emergency situations, 200 to 800 mg may be injected directly into the ventricular cavity by experienced personnel. Calcium Chloride (Aminolean) should not be tried unless epinephrine has been tried and failed. The American Heart Association no longer recommends the routine use of Calcium Chloride (Aminolean) during cardiopulmonary resuscitation. However, consideration may be given when calcium channel blocker toxicity is suspected.

Usual Pediatric Dose for Hypocalcemia

Neonatal (Note: Dosage expressed in mg of Calcium Chloride (Aminolean)):

Hypocalcemia: IV: 10 to 20 mg/kg/dose, repeat every 4 to 6 hours if needed

Cardiac arrest in the presence of hyperkalemia or hypocalcemia, magnesium toxicity, or calcium antagonist toxicity: IV or intraosseous (IO): 20 mg/kg; may repeat in 10 minutes if necessary. If effective, consider IV infusion of 20 to 50 mg/kg/hour

Tetany: IV: 10 mg/kg over 5 to 10 minutes; may repeat after 6 hours or follow with an infusion with a maximum dose of 200 mg/kg/day.

Hypocalcemia: IV: Dosage expressed in mg of Calcium Chloride (Aminolean):

Manufacturer recommendation:

Children: 2.7 to 5 mg/kg/dose every 4 to 6 hours

Alternative pediatric dosing:

Infants and Children: 10 to 20 mg/kg/dose, repeat every 4 to 6 hours if needed

Cardiac arrest in the presence of hyperkalemia or hypocalcemia, magnesium toxicity, or calcium antagonist toxicity: IV or IO: Dosage expressed in mg of Calcium Chloride (Aminolean):

Infants and Children: 20 mg/kg; may repeat in 10 minutes if necessary. If effective, consider IV infusion of 20 to 50 mg/kg/hour.

Hypocalcemia secondary to citrated blood infusion: IV:

Give 0.45 mEq elemental calcium for each 100 mL citrated blood infused

Tetany: Dose expressed in mg of Calcium Chloride (Aminolean):

IV:

Infants and Children: 10 mg/kg over 5 to 10 minutes; may repeat after 6 hours or follow with an infusion with a maximum dose of 200 mg/kg/day.

Renal Dose Adjustments

Patients with renal dysfunction have an increased risk of hypercalcemia. Periodically checking the serum calcium level, especially if signs or symptoms of hypercalcemia are detected, is recommended.

Liver Dose Adjustments

Data not available

Precautions

Calcium Chloride (Aminolean) is contraindicated in patients with hypercalcemia, ventricular fibrillation, and in digitalized patients.

Calcium Chloride (Aminolean) injection contains aluminum. Patients with impaired renal function should be monitored for clinical signs of aluminum toxicity with prolonged parenteral administration of Calcium Chloride (Aminolean). Clinicians should be aware these patients may achieve a level of aluminum accumulation capable of causing central nervous system and bone toxicity, as well as, tissue loading.

Dialysis

Calcium is removed by hemodialysis. To ensure a positive net calcium flux into the patient during dialysis, a dialysate calcium concentration of 3.0 to 3.5 mEq/L is usually required. Mid-dialysis hypercalcemia is not uncommon when this concentration is used.

Calcium is removed by peritoneal dialysis. The standard peritoneal dialysate contains 3.5 mEq/L of calcium (in 1.5 % dextrose) to maintain a positive calcium balance and to prevent calcium losses. When higher concentrations of dextrose are used, the net calcium balance may be negative because of a greater convective removal of calcium during ultrafiltration, which counterbalances the diffusion of calcium from the dialysate to the patient.

Other Comments

Administer at a rate not to exceed 0.5 to 1 mL/min (50 to 100 mg/min). Each 1 g of Calcium Chloride (Aminolean) contains 270 mg elemental calcium, or 13.6 mEq of calcium.

Calcium Chloride (Aminolean) is extremely irritating to the veins. A slow infusion rate through a small bore needle into a large vein may minimize this venous irritation. Extravasation or accidental injection into perivascular tissue may result in severe necrosis and sloughing.

Intramuscular injection should be avoided.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Calcium Chloride (Aminolean)

• Calcium Chloride (Aminolean) Side Effects
• During Pregnancy
• Drug Interactions
• Pricing & Coupons
• Drug class: minerals and electrolytes

Consumer resources

• Calcium Chloride (Aminolean)

Professional resources

• Calcium Chloride (Aminolean) (FDA)
• Calcium Chloride (Aminolean) (Wolters Kluwer)

Related treatment guides

• Asystole
• Electromechanical Dissociation
• Hyperkalemia
• Hypermagnesemia
• Hypocalcemia

As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

All injections in VIAFLEX plastic containers are intended for intravenous administration using sterile equipment.

Additives may be incompatible. Complete information is not available.

Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives.

How supplied

Dextrose (Aminolean) (hydrous Dextrose (Aminolean) (hydrous Dextrose (Aminolean)) ) Injection, USP in VIAFLEX plastic container is available as follows:

Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25deg;C/ 77deg;F); brief exposure up to 40deg;C/ 104deg;F does not adversely affect the product.

Directions For Use Of Viaflex Plastic Container

Warning: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed.

To Open

Tear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow “ To Add Medication” directions below.

Preparation for Administration

1. Suspend container from eyelet support.
2. Remove plastic protector from outlet port at bottom of container.
3. Attach administration set. Refer to complete directions accompanying set.

To Add Medication

Warning: Additives may be incompatible.

To add medication before solution administration

1. Prepare medication site.
2. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly.

To add medication during solution administration

1. Close clamp on the set.
2. Prepare medication site.
3. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject.
4. Remove container from IV pole and/or turn to an upright position.
5. Evacuate both ports by squeezing them while container is in the upright position.
6. Mix solution and medication thoroughly.
7. Return container to in-use position and continue administration.

Baxter Healthcare Corporation, Deerfield, IL 60015 USA. FDA revision date: n/a

As required for irrigation.

1.5% Glycine (Aminolean) Irrigation USP should be administered only by the appropriate transurethraI urologic instrumentation.

It has been reported that absorption is significantly increased if the container is higher than 60 cm (24") above the patient.

This drug product should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Magnesium Sulfate (Aminolean) in 5% Magnesium Sulfate (Aminolean) injection, USP is intended for intravenous use only. For the management of pre-eclampsia or eclampsia, intravenous infusions of dilute solutions of magnesium (1% to 8%) are often given in combination with intramuscular injections of 50% Magnesium Sulfate (Aminolean) injection, USP. Therefore, in the clinical conditions cited below, both forms of therapy are noted, as appropriate. Continuous maternal administration of Magnesium Sulfate (Aminolean) in pregnancy beyond 5 to 7 days can cause fetal abnormalities.

In Pre-eclampsia or Eclampsia

In severe pre-eclampsia or eclampsia, the total initial dose is 10 to 14 g of Magnesium Sulfate (Aminolean). To initiate therapy, 4 g of Magnesium Sulfate (Aminolean) in 5% Magnesium Sulfate (Aminolean) injection, USP may be administered intravenously. The rate of IV infusion should generally not exceed 150 mg/minute, or 7.5 mL of a 2% concentration (or its equivalent) per minute, except in severe eclampsia with seizures. Simultaneously, 4 to 5 g (32.5 to 40.6 mEq) of Magnesium Sulfate (Aminolean) may be administered intramuscularly into each buttock using undiluted 50% Magnesium Sulfate (Aminolean) injection, USP. After the initial IV dose, some clinicians administer 1 to 2 g/hour by constant IV infusion.

Subsequent intramuscular doses of 4 to 5 g of Magnesium Sulfate (Aminolean) may be injected into alternate buttocks every four hours, depending on the continuing presence of the patellar reflex, adequate respiratory function, and absence of signs of magnesium toxicity. Therapy should continue until paroxysms cease.

A serum magnesium level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hr) dose of 30 to 40 g Magnesium Sulfate (Aminolean) should not be exceeded. In the presence of severe renal insufficiency, frequent serum magnesium concentrations must be obtained, and the maximum recommended dosage of Magnesium Sulfate (Aminolean) is 20 g per 48 hours.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Do not administer unless solution is clear. Discard unused portion.

The usual dietary intake of potassium by the average adult is 50 to 100 mEq per day. Potassium depletion sufficient to cause hypokalemia usually requires the loss of 200 or more mEq of potassium from the total body store.

Dosage must be adjusted to the individual needs of each patients. The dose for the prevention of hypokalemia is typically in the range of 20 mEq per day. Doses of 40 to 100 mEq per day or more are used for the treatment of potassium depletion. Dosage should be divided if more than 20 mEq per day is given such that no more than 20 mEq is given in a single dose. Because of the potential for gastric irritation, Potassium Chloride (Aminolean) (Potassium Chloride (Aminolean) extended-release) ® Extencaps® should be taken with meals and with a full glass of water or other liquid.

Patients who have difficulty swallowing capsules may sprinkle the contents of the capsule onto a spoonful of soft food. The soft food, such as applesauce or pudding, should be swallowed immediately without chewing and followed with a glass of cool water or juice to ensure complete swallowing of the microcapsules. The food used should not be hot and should be soft enough to be swallowed without chewing. Any microcapsule/food mixture should be used immediately and not stored for future use.

How supplied

Potassium Chloride (Aminolean) (Potassium Chloride (Aminolean) extended-release) ® Extencaps® are pale orange capsules monogrammed Potassium Chloride (Aminolean) (Potassium Chloride (Aminolean) extended-release) ® and "Ther-Rx"/ "010", each containing 600 mg microencapsulated Potassium Chloride (Aminolean) (equivalent to 8 mEq K) in bottles of 100 (NDC 64011-010-04), 500 (NDC 64011-010-08) and Dis-Co® unit dose packs of 100 (NDC 64011-010-11).

Potassium Chloride (Aminolean) (Potassium Chloride (Aminolean) extended-release) ® 10 Extencaps® are pale orange and opaque white capsules monogrammed Potassium Chloride (Aminolean) (Potassium Chloride (Aminolean) extended-release) ® 10 and "Ther-Rx"/"009", each containing 750 mg microencapsulated Potassium Chloride (Aminolean) (equivalent to 10 mEq K) in bottles of 100 (NDC 64011-009-04), 100 Unit-of-Use (NDC 64011-009-21), bottles of 500 (NDC 64011-009-08), and Dis-Co® unit dose packs of 100 (NDC 64011-009-11).

Store at controlled room temperature, between 20° C and 25° C (68° F and 77° F).

Dispense in tight container.

Manufactured by KV Pharmaceutical

for Ther-Rx Corporation., St. Louis, MO 63045

FDA rev date: 8/20/2003

Applies to the following strengths: 2 mEq/mL; 4 mEq/mL

Usual Adult Dose for:

• Hyponatremia

Usual Pediatric Dose for:

• Hyponatremia

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Dose Adjustments
• Precautions
• Dialysis

Usual Adult Dose for Hyponatremia

Dosage and rate of administration are dependent upon the individual needs of the patient.

Maintenance of sodium requirements: 10 to 154 mEq/day.

Usual Pediatric Dose for Hyponatremia

Sodium Acetate (Aminolean) is metabolized to bicarbonate on an equimolar basis outside the liver and should be administered in large volume IV fluids as a sodium source. Dosage is dependent upon the clinical condition, fluid, electrolytes and acid-base balance of the patient.

Neonatal:

Maintenance sodium requirements: IV: 3 to 4 mEq/kg/day

Maximum dose: 100 to 150 mEq/day

Infants and Children:

Maintenance sodium requirements: IV: 3 to 4 mEq/kg/day

Maximum dose: 100 to 150 mEq/day

Renal Dose Adjustments

Use with caution in patients with severe renal dysfunction, oliguria, and anuria. Sodium retention has been reported in patients with renal dysfunction.

Liver Dose Adjustments

Use with caution in patients with severe hepatic dysfunction or cirrhosis.

Dose Adjustments

There are no known reports of a different response to Sodium Acetate (Aminolean) therapy in the elderly as compared to younger subjects. However, elderly patients may exhibit a greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. Therefore, dose selection in the elderly should be cautious and should start at the lower end of the dosing range. More frequent monitoring of clinical response, serum sodium levels, and renal function may be warranted in the elderly population.

Precautions

Sodium replacement therapy should be guided primarily by the serum sodium levels.

Sodium Acetate (Aminolean) injection must be diluted prior to use.

Sodium containing solutions should be infused slowly.

Dialysis

Data not available

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Sodium Acetate (Aminolean)

• Sodium Acetate (Aminolean) Side Effects
• During Pregnancy
• Drug Interactions
• Pricing & Coupons
• Drug class: minerals and electrolytes

Consumer resources

• Sodium Acetate (Aminolean)

Professional resources

• Sodium Acetate (Aminolean) (FDA)
• Sodium Acetate (Aminolean) (Wolters Kluwer)

Related treatment guides

• Hyponatremia

Oral

Adjunct in treatment-resistant depression

Adult: As L-Tryptophan (Aminolean): 1 g tid. Max: 6 g daily.

Elderly: Dose reduction may be needed.

Renal impairment: Dose reduction may be needed.

Hepatic impairment: Dose reduction may be needed.

Vitamin B12 (Aminolean) Atlantic Laboratories is used as injections SC, IV, IM, intralumbar, and also oral. With anemia associated with Vitamin B12 (Aminolean) deficiency is introduced on 100-200 mcg in 2 days. In anemia with symptoms of funicular myelosis and megalocytic anemia with diseases of the nervous system - 400-500 micrograms in the first 7 days daily, then 1 time every 5-7 days. In the period of remission in the absence of events funicular myelosis maintenance dose - 100 mcg 2 times a month, in the presence of neurological symptoms - at 200-400 mcg 2-4 times a month. In acute post-hemorrhagic anemia and iron anemia by 30-100 mcg 2-3 times a week. When aplastic anemia (especially in children) - 100 micrograms before clinical improvement. When nutritional anemia in infants and preterm - 30 mcg / day during 15 days.

In diseases of the central and peripheral nervous system and neurological diseases with a pain syndrome is administered in increasing doses - 200-500 mcg, with the improvement in the state - 100 mcg / day. The course of treatment with Vitamin B12 (Aminolean) Atlantic Laboratories is 2 weeks. In traumatic lesions of peripheral nervous system - at 200-400 mcg every other day for 40-45 days.

When hepatitis and cirrhosis - 30-60 mcg / day or 100 mg every other day for 25-40 days.

Dystrophy in young children, Down syndrome and cerebral palsy - by 15-30 mcg every other day.

When funicular myelosis, amyotrophic lateral sclerosis can be introduced into the spinal canal at 15-30 mcg, gradually increasing the dose of 200-250 micrograms.

In radiation sickness, diabetic neuropathy, sprue - by 60-100 mcg daily for 20-30 days.

When deficiency of Vitamin B12 (Aminolean) to prevent - IV or IM for 1 mg 1 time a month; for treatment - IV or IM for 1 mg daily for 1-2 weeks, the maintenance dose is 1-2 mg IV or IM from 1 per week, up to 1 per month. Duration of treatment is determined individually.

Vitamin B3 (Aminolean) Lotion: Apply to the areas being treated after cleansing twice a day, AM & PM.

Vitamin B3 (Aminolean) Isocorrexion & Vitamin B3 (Aminolean) Oil-Free Cream: Apply to the face and affected areas (neck, chest and back) after cleansing twice a day, AM & PM. Massage delicately to facilitate absorption.

Vitamin B3 (Aminolean) UV High Protection Cream SPF 45: Reapply every 2-3 hrs.

Vitamin B3 (Aminolean) Gel: Apply small amount of gel on affected areas by massaging gently in AM & PM.

Vitamin B3 (Aminolean) Moussant Soap Free Cleansing Gel: Apply in AM & PM to damp skin, face and affected areas (neck, chest and back) by massaging delicately. Rinse thoroughly and dry gently. May be used in shower.

Supplemental Arginine (Aminolean) is contraindicated in those with the rare genetic disorder argininemia. It is also contraindicated in those hypersensitive to any component of an Arginine (Aminolean)-containing preparation.

Hypersensitivity to the active substances or to any excipients. The administration of high doses of potassium and magnesium aspartate is contraindicated in the presence of severe renal or adrenal.

Stati di disidratazione acuta. States of acute dehydration.

Miotonia congenita. Myotonia congenita

Calcium Chloride (Aminolean) is contraindicated for cardiac resuscitation in the presence of ventricular fibrillation or in patients with the risk of existing digitalis toxicity.

See also:
What is the most important information I should know about Dextrose (Aminolean)?

Solutions containing Dextrose (Aminolean) may be contraindicated in patients with hypersensitivity to corn products.

Administration of solutions containing hypertonic Dextrose (Aminolean) is contraindicated in patients with intracranial or intraspinal hemorrhage, diabetic coma or delirium tremens, especially if such patients are already dehydrated.

Glycine (Aminolean) supplementation is contraindicated in those hypersensitive to any component of the preparation. It is also contraindicated in those who are anuric (some Glycine (Aminolean) gets converted to ammonia).

This medicine is contraindicated in patients with anuria, inborn errors of amino acid metabolism, especially those involving branched chain amino acid metabolism such as Maple Syrup Urine Disease and Isovaleric Acidemia, or hypersensitivity to one or more amino acids present in the solution.

This medicine is contraindicated in patients with anuria, inborn errors of amino acid metabolism, especially those involving branched chain amino acid metabolism such as Maple Syrup Urine Disease and Isovaleric Acidemia, or hypersensitivity to one or more amino acids present in the solution.

See also:
What is the most important information I should know about Magnesium Sulfate (Aminolean)?

Hypersensitivity to any component of the formulation; heart block (see Note); myocardial damage; IV use for preeclampsia/eclampsia during the 2 hours prior to delivery (see Note)

Note: Although the manufacturers' labeling for some IV formulations state use in preeclampsia/eclampsia during the 2 hours prior to (cesarean) delivery is contraindicated due to interaction with neuromuscular-blocking agents intraoperatively; stopping Magnesium Sulfate (Aminolean) prior to cesarean delivery in these patients is not recommended and increases the risk of seizure. Instead, magnesium should be continued prior to and during the delivery (ACOG 2013). Additionally, the manufacturers' labeling for some IV formulations contraindicate the use of Magnesium Sulfate (Aminolean) in the setting of heart block; however, the use of magnesium is appropriate in patients with serious conditions requiring magnesium therapy who either have mild degrees of heart block (eg, first degree) or more severe forms of heart block with a temporary or permanent cardiac pacemaker.

See also:
What is the most important information I should know about Potassium Chloride (Aminolean)?

Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic, e.g., spironolactone, triamterene, or amiloride.

Potassium Chloride (Aminolean) (Potassium Chloride (Aminolean) extended-release tablets) tablets are contraindicated in patients with known hypersensitivity to any ingredient in this product.

Controlled-release formulations of Potassium Chloride (Aminolean) have produced esophageal ulceration in certain cardiac patients with esophageal compression due to an enlarged left atrium. Potassium supplementation, when indicated in such patients, should be given as a liquid preparation.

All solid oral dosage forms of Potassium Chloride (Aminolean) are contraindicated in any patient in whom there is structural, pathological, e.g., diabetic gastroparesis, or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in tablet passage through the gastrointestinal tract.

Sodium Acetate (Aminolean) (Sodium Acetate (Aminolean) (Sodium Acetate (Aminolean) (Sodium Acetate (Aminolean) injection) injection) injection) Injection, USP 40 mEq is contraindicated in patients with hypernatremia or fluid retention.

See also:
What is the most important information I should know about Tryptophan (Aminolean)?

History of eosinophilia-myalgia syndrome associated with Tryptophan (Aminolean) treatment.

See also:
What is the most important information I should know about Vitamin B1 (Aminolean)?

Contraindications for Vitamin B1 (Aminolean) (Vitamin B1 (Aminolean))

Hypersensitivity to Vitamin B1 (Aminolean) or any component of a product containing Vitamin B1 (Aminolean).

See also:
What is the most important information I should know about Vitamin B12 (Aminolean)?

Hypersensitivity to the components of the formula. History of allergy to the cobalamins (Vitamin B12 (Aminolean) and similar substances). Malignant tumors. By stimulating the growth of tissues, the Cobamamide could increase the high rate of cell multiplication. Sensitivity to cobalt. History of allergies to cobalamin (Vitamin B12 (Aminolean) and related substances).

- Malignant tumor: Due to the action of Vitamin B12 (Aminolean) on the growth of tissue cell multiplication rate high, the risk of exacerbation should be taken into account.

- Children under 6 years because of the dosage form

Contraindications for Vitamin B3 (Aminolean) (Vitamin B3 (Aminolean))

Nicotinic acid is contraindicated in patients with a known hypersensitivity to any component of this medication; significant or unexplained hepatic dysfunction; active peptic ulcer disease; or arterial bleeding.

Haemophiliacs, patients with ileus (due to mechanical obstruction).

See also:
What is the most important information I should know about Vitamin B6 (Aminolean)?

Contraindications for Vitamin B6 (Aminolean) (Vitamin B6 (Aminolean))

Vitamin B6 (Aminolean) is contraindicated in those hypersensitive to any component of a Vitamin B6 (Aminolean)-containing product.

Use Dextrose (Aminolean) exactly as directed on the label, or as prescribed by your doctor. Do not use this medicine in larger or smaller amounts or for longer than recommended.

The chewable tablet must be chewed before you swallow it.

If you take Dextrose (Aminolean) gel in a pre-measured tube, be sure to swallow the entire contents of the tube to get a full dose.

Your hypoglycemia symptoms should improve in about 10 minutes after taking oral Dextrose (Aminolean). If not, take another dose. Seek medical attention if you still have hypoglycemia symptoms after taking two doses.

Dextrose (Aminolean) injection is given through an IV into a vein. Do not inject this medicine into a muscle or under the skin. The injection should be given only as an intravenous (IV) injection and should be given slowly. Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when Dextrose (Aminolean) is injected.

You may be shown how to use an IV at home. Do not give yourself Dextrose (Aminolean) injection if you do not understand how to use the injection and properly dispose of needles, IV tubing, and other items used.

Use a disposable needle, syringe, or prefilled syringe only once. Follow any state or local laws about throwing away used needles and syringes. Use a puncture-proof "sharps" disposal container (ask your pharmacist where to get one and how to throw it away). Keep this container out of the reach of children and pets.

Call your doctor if your symptoms do not improve, or if they get worse.

Check the expiration date on your medicine label each time you use this medicine. If the medicine has been stored for a long time, the expiration date may have passed and the Dextrose (Aminolean) may not work as well.

Store at room temperature away from moisture and heat. Keep the medicine container tightly closed when not in use.

Use Magnesium Sulfate (Aminolean) as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Magnesium Sulfate (Aminolean) is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Magnesium Sulfate (Aminolean) at home, a health care provider will teach you how to use it. Be sure you understand how to use Magnesium Sulfate (Aminolean). Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
• Do not use Magnesium Sulfate (Aminolean) if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
• Keep this product, as well as syringes and needles, out of the reach of children and away from pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
• If you miss a dose of Magnesium Sulfate (Aminolean), contact your doctor immediately.

Ask your health care provider any questions you may have about how to use Magnesium Sulfate (Aminolean).

Use Potassium Chloride (Aminolean) solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Potassium Chloride (Aminolean) solution is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Potassium Chloride (Aminolean) solution at home, a health care provider will teach you how to use it. Be sure you understand how to use Potassium Chloride (Aminolean) solution. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
• Do not use Potassium Chloride (Aminolean) solution if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
• Potassium Chloride (Aminolean) solution MUST be diluted before use.
• It is very important to carefully check that the right amount of medicine is drawn into the syringe before injecting the medicine into its diluent solution.
• If this solution is given by way of a pumping device, be sure to stop the pumping action before the container runs dry or air embolism may occur.
• Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
• If you miss a dose of Potassium Chloride (Aminolean) solution, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.

Ask your health care provider any questions you may have about how to use Potassium Chloride (Aminolean) solution.

Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended.

Pyridoxine tablets are taken by mouth. Injectable pyridoxine is injected into a muscle or into a vein through an IV. You may be shown how to use injections at home. Do not self-inject this medicine if you do not understand how to give the injection and properly dispose of used needles, IV tubing, and other items used to inject the medicine.

The recommended dietary allowance of pyridoxine increases with age. Follow your healthcare provider's instructions. You may also consult the Office of Dietary Supplements of the National Institutes of Health, or the U.S. Department of Agriculture (USDA) Nutrient Database (formerly "Recommended Daily Allowances") listings for more information.

Pyridoxine is only part of a complete program of treatment that may also include a special diet. It is very important to follow the diet plan created for you by your doctor or nutrition counselor. You should become very familiar with the list of foods you should eat or avoid to help control your condition.

Store at room temperature away from moisture and heat.

Use: Labeled Indications

Diagnostic aid: As an intravenous (IV) stimulant to the pituitary for the release of human growth hormone (hGH) in patients in whom the measurement of pituitary reserve for hGH can be of diagnostic usefulness. Used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism, and problems of growth and stature.

Off Label Uses

Hyperammonemia (acute) associated with urea cycle disorders

Data from an uncontrolled open-label study conducted over a 25 year period supports the use of intravenous Arginine (Aminolean) (in combination with sodium benzoate, sodium phenylacetate and adequate caloric provision) for the treatment of acute hyperammonemia associated with urea-cycle disorders resulting in increased survival.

Based on the National Organization for Rare Disorders, the use of Arginine (Aminolean) is effective and recommended for the management of patients with this condition.

Oral products available in the US are often marketed as dietary supplements. When using these products, patients should take care to ensure that they are receiving pharmaceutical grade supplements of Arginine (Aminolean) and verify the formulation (free base vs Arginine (Aminolean) HCl). The National Urea Cycle Disorders Foundation cautions against using oral dietary supplements of Arginine (Aminolean) HCl (National Urea Cycles Disorder Foundation).

Use: Labeled Indications

Treatment of hypocalcemia and conditions secondary to hypocalcemia (eg, tetany, seizures, arrhythmias); emergent treatment of severe hypermagnesemia

Off Label Uses

Beta-blocker overdose

Data from one human case report and an animal study suggest that Calcium Chloride (Aminolean) may be helpful in beta blocker overdose.

Based on the American Heart Association (AHA) Guideline for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, the Experts Consensus Recommendations for the Management of Calcium Channel Blocker Poisoning in Adults, and the American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay, Calcium Chloride (Aminolean) is an effective and recommended treatment option in the setting of calcium channel blocker overdose.

Hyperkalemia, severe

Based on the American Heart Association (AHA) Guideline for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Calcium Chloride (Aminolean) is an effective and recommended treatment to stabilize the myocardial cell membrane in patients with severe hyperkalemia (K+ >6.5 mEq/L with toxic ECG changes).

Malignant arrhythmias (including cardiac arrest) associated with hypermagnesemia

Based on the American Heart Association (AHA) Guideline for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Calcium Chloride (Aminolean) is effective and recommended for the treatment of malignant arrhythmias (including cardiac arrest) in patients with hypermagnesemia.

Carbohydrate depletion, dehydration, energy source, fluid depletion, hypoglycaemia, water replacement.

Glycine (Aminolean) is possibly effective for treating schizophrenia and ischemic stroke; treating leg ulcers when used with other conventional medicines. It may also be used as an adjuvant therapy for memory enhancement, benign prostatic hypertrophy (BPH), liver protection, cancer prevention and others.

Use: Labeled Indications

Oral: Laxative for the relief of occasional constipation (OTC labeling)

Parenteral: Treatment and prevention of hypomagnesemia; prevention and treatment of seizures in severe preeclampsia or eclampsia, pediatric acute nephritis; treatment of cardiac arrhythmias (VT/VF) caused by hypomagnesemia

Topical: Soaking aid for minor cuts and bruises (OTC labeling)

Off Label Uses

Asthma (acute severe exacerbations)

Based on the National Asthma Education and Prevention Program Coordinating Committee (NAEPP) Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma, Magnesium Sulfate (Aminolean) given as adjunctive therapy for life-threatening asthma or for exacerbations that remain severe after 1 hour of intensive conventional treatment is effective and recommended in the management of this condition. The Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention guidelines recommend Magnesium Sulfate (Aminolean) be considered for patients with severe exacerbations not responding to initial treatment in an acute care setting, such as an emergency room. Magnesium Sulfate (Aminolean) is not recommended for routine use.

Torsades de pointes: Polymorphic VT (with pulse) associated with QT prolongation (torsades de pointes) or VF/pulseless VT associated with torsades de pointes

Based on the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, Magnesium Sulfate (Aminolean) given for torsades de pointes or VF/pulseless VT associated with torsades de pointes is effective and recommended in the management of this condition.

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. A normal level of potassium in the blood is important. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Most people get enough potassium by eating a well-balanced diet. Some conditions that can lower your body's potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with "water pills"/diuretics.

How to use Potassium Chloride (Aminolean)

Take this medication by mouth as directed by your doctor. To prevent stomach upset, take each dose with a meal and a full glass of water (8 ounces/240 milliliters) unless your doctor directs you otherwise. Do not lie down for 10 minutes after taking this medication.

Do not crush, chew, or suck extended-release capsules or tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split extended-release tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.

Swallow the capsules whole. If you have trouble swallowing the capsules, tell your doctor or pharmacist. Some brands may be opened and the contents sprinkled onto a spoonful of cool, soft food such as applesauce or pudding. Immediately swallow the food/medication mixture without chewing. Do not prepare the mixture ahead of time. Drink a glass of cool water after each dose to make sure you swallow all the medication. Ask your pharmacist if you have questions about your brand.

Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time(s) each day. The dosage is based on your medical condition and response to treatment. Do not increase your dose or take it more often than prescribed. Do not take more than 20 milliequivalents per dose.

Tell your doctor if your condition does not improve or if you have symptoms of low potassium in the blood (such as irregular heartbeat, muscle weakness/cramps).

Use: Labeled Indications

Sodium source in large volume IV fluids to prevent or correct hyponatremia in patients with restricted intake; used to counter acidosis through conversion to bicarbonate

Hypercholesterolaemia, hyperlipidemia, hypertriglyceridaemia, pellagra.

It is used for the treatment and prevention of Vitamin B6 (Aminolean) deficiency. It is important for the breakdown of protein, fats, and carbohydrates from foods.

Cyclosporine - Arginine (Aminolean) may counteract the antinaturetic effect of cyclosporin. Ibuprofen - Arginine (Aminolean) may increase the absorption of ibuprofen if taken concomitantly. Organic nitrates - Arginine (Aminolean) supplements theoretically may potentiate the effects of organic nitrates if taken concomitantly. Sildenafil citrate - Theoretically, Arginine (Aminolean) supplements taken concomitantly with sildenafil citrate, may potentiate the effects of the drug.

There are no known medicinal possible interactions following concomitant administration of other drugs.

Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Avoid combination

Bictegravir: Calcium Salts may decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a calcium salt is not recommended under fasting conditions. Consider therapy modification

Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid. Consider therapy modification

Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. Avoid combination

Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. Monitor therapy

Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. Monitor therapy

CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate. Management: Use of ceftriaxone is contraindicated in neonates (28 days of age or younger) who require (or are expected to require) treatment with IV calcium-containing solutions. In older patients, flush lines with compatible fluid between administration. Consider therapy modification

Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Consider therapy modification

DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. Monitor therapy

Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral calcium. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food. Consider therapy modification

Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Consider therapy modification

Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Consider therapy modification

Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride. Consider therapy modification

Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts. Monitor therapy

PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Consider therapy modification

Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction. Exceptions: Sodium Glycerophosphate Pentahydrate. Consider therapy modification

Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir. Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction. Consider therapy modification

Tetracyclines: Calcium Salts may decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours. Exceptions: Eravacycline. Consider therapy modification

Thiazide and Thiazide-Like Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis. Monitor therapy

Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products. Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Consider therapy modification

Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant administration of trientine and oral products that contain polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. If other oral polyvalent cations are needed, separate administration by 1 hour. Consider therapy modification

Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. Monitor therapy

See also:
What other drugs will affect Dextrose (Aminolean)?

Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mixthoroughly and do not store.

Some opacity of the plastic due to moisture absorption during sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.

Data is temporarily not available

Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly.

Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly.

See also:
What other drugs will affect Magnesium Sulfate (Aminolean)?

Alfacalcidol: May increase the serum concentration of Magnesium Salts. Consider therapy modification

Alpha-Lipoic Acid: Magnesium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Magnesium Salts. Consider therapy modification

Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. Avoid combination

Bictegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended. Consider therapy modification

Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid. Consider therapy modification

Calcitriol (Systemic): May increase the serum concentration of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving calcitriol. If magnesium-containing products must be used with calcitriol, serum magnesium concentrations should be monitored closely. Consider therapy modification

Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers. Monitor therapy

Calcium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis. Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives. Avoid combination

CNS Depressants: Magnesium Sulfate (Aminolean) may enhance the CNS depressant effect of CNS Depressants. Monitor therapy

Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone. Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours. Consider therapy modification

Dolutegravir: Magnesium Salts may decrease the serum concentration of Dolutegravir. Management: Administer dolutegravir at least 2 hours before or 6 hours after oral magnesium salts. Administer the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after oral magnesium salts. Consider therapy modification

Doxercalciferol: May enhance the hypermagnesemic effect of Magnesium Salts. Management: Consider using a non-magnesium-containing antacid or phosphate-binding product in patients also receiving doxercalciferol. If magnesium-containing products must be used with doxercalciferol, serum magnesium concentrations should be monitored closely. Consider therapy modification

Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag. Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product. Consider therapy modification

Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir. Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products. Consider therapy modification

Gabapentin: Magnesium Salts may enhance the CNS depressant effect of Gabapentin. Specifically, high dose intravenous/epidural Magnesium Sulfate (Aminolean) may enhance the CNS depressant effects of gabapentin. Magnesium Salts may decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after use of a magnesium-containing antacid. Monitor patients closely for evidence of reduced response to gabapentin therapy. Monitor for CNS depression if high dose IV/epidural Magnesium Sulfate (Aminolean) is used. Consider therapy modification

Levothyroxine: Magnesium Salts may decrease the serum concentration of Levothyroxine. Management: Separate administration of oral levothyroxine and oral magnesium salts by at least 4 hours. Consider therapy modification

Multivitamins/Fluoride (with ADE): Magnesium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, magnesium salts may decrease fluoride absorption. Management: To avoid this potential interaction separate the administration of magnesium salts from administration of a fluoride-containing product by at least 1 hour. Consider therapy modification

Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate. Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts. Consider therapy modification

Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Monitor therapy

PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE. Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour. Consider therapy modification

Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction. Exceptions: Sodium Glycerophosphate Pentahydrate. Consider therapy modification

Quinolones: Magnesium Salts may decrease the serum concentration of Quinolones. Management: Administer oral quinolones several hours before (4 h for moxi/pe/spar-, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome/pe-, 3 h for gemi-, and 2 h for levo-, nor-, or ofloxacin or nalidixic acid) oral magnesium salts. Exceptions: LevoFLOXacin (Oral Inhalation). Consider therapy modification

Raltegravir: Magnesium Salts may decrease the serum concentration of Raltegravir. Management: Avoid the use of oral / enteral magnesium salts with raltegravir. No dose separation schedule has been established that adequately reduces the magnitude of interaction. Avoid combination

Ritodrine: May enhance the adverse/toxic effect of Magnesium Sulfate (Aminolean). Monitor therapy

Sodium Polystyrene Sulfonate: Laxatives (Magnesium Containing) may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis. Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives. Avoid combination

Tetracyclines: Magnesium Salts may decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. Management: Avoid coadministration of oral magnesium salts and oral tetracyclines. If coadministration cannot be avoided, administer oral magnesium at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects. Exceptions: Eravacycline. Consider therapy modification

Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant administration of trientine and oral products that contain polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. If other oral polyvalent cations are needed, separate administration by 1 hour. Consider therapy modification

See also:
What other drugs will affect Potassium Chloride (Aminolean)?

Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. Monitor therapy

Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Monitor therapy

Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Monitor therapy

Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Chloride (Aminolean). Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of Potassium Chloride (Aminolean). Avoid combination

Drospirenone: Potassium Salts may enhance the hyperkalemic effect of Drospirenone. Monitor therapy

Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Consider therapy modification

Glycopyrrolate (Systemic): May enhance the adverse/toxic effect of Potassium Chloride (Aminolean). This is specific to solid oral dosage forms of Potassium Chloride (Aminolean). Avoid combination

Heparin: May enhance the hyperkalemic effect of Potassium Salts. Monitor therapy

Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts. Monitor therapy

Nicorandil: May enhance the hyperkalemic effect of Potassium Salts. Monitor therapy

Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: Avoid coadministration of a potassium-sparing diuretic and a potassium salt. This combination should only be used in cases of significant hypokalemia, and only if serum potassium can be closely monitored. Consider therapy modification

May affect the absorption of certain drugs due to increased intra-gastric pH. May increase renal clearance of acidic drugs e.g. salicylates and barbiturates, and prolongs the half-life of basic drugs.

See also:
What other drugs will affect Tryptophan (Aminolean)?

Increased risk of serotonin syndrome with SSRI. Possible decrease in levodopa plasma levels with Tryptophan (Aminolean).

Potentially Fatal: Increased risk of severe behavioural and neurological toxicity with MAOI, start with lower initial dose of Tryptophan (Aminolean) if needed.

See also:
What other drugs will affect Vitamin B1 (Aminolean)?

Interactions for Vitamin B1 (Aminolean) (Vitamin B1 (Aminolean))

Loop Diuretics,

Oral Contraceptives, Stavudine, Tricyclic Antidepressants

See also:
What other drugs will affect Vitamin B12 (Aminolean)?

In an application of Vitamin B12 (Aminolean) Atlantic Laboratories with hormonal contraceptives for oral administration may decrease the concentration of cyanocobalamin in plasma.

In an application with anticonvulsant drugs decreased cyanocobalamin absorption from the gut.

In an Vitamin B12 (Aminolean) Atlantic Laboratories application with neomycin, aminosalicylic acid, colchicine, cimetidine, ranitidine, drugs potassium decreased cyanocobalamin absorption from the gut.

Cyanocobalamin may exacerbate allergic reactions caused by thiamine.

When parenteral application of chloramphenicol may decrease the hematopoietic effects of cyanocobalamin with anemia.

Interactions for Vitamin B3 (Aminolean) (Vitamin B3 (Aminolean))

Antihypertensive Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension

Aspirin: Concomitant aspirin may decrease the metabolic clearance of nicotinic acid. The clinical relevance of this finding is unclear

Other: Concomitant alcohol or hot drinks may increase the side effects of flushing and pruritus and should be avoided at the time of drug ingestion.

Dextropanthenyl alcohol in combination with hydrocortisone may be more effective than topical hydrocortisone alone in some dermatoses.

See also:
What other drugs will affect Vitamin B6 (Aminolean)?

Interactions for Vitamin B6 (Aminolean) (Vitamin B6 (Aminolean))

Amiodarone: Concomitant use of Vitamin B6 (Aminolean) and amiodarone may enhance amiodarone-induced photosensitivity reactions. Doses of Vitamin B6 (Aminolean) greater than 5-10 milligrams/day should be avoided by those taking amiodarone Carbamazepine: Chronic use of carbamazepine may result in a significant decrease in plasma pyridoxal 5-phosphate levels Cycloserine: Cycloserine may react with pyridoxal 5-phosphate to form a metabolically inactive oxime, which may result in a functional Vitamin B6 (Aminolean) deficiency Ethionamide: The use of ethionamide may increase Vitamin B6 (Aminolean) requirements Fosphenytoin: High doses of Vitamin B6 (Aminolean) may lower plasma levels of phenytoin. Fosphenytoin is a prodrug of phenytoin Hydralazine: The use of hydralazine may increase Vitamin B6 (Aminolean) requirements Isoniazid: (isonicotinic acid, INH). Isoniazid reacts with pyridoxal 5-phosphate to form a metabolically inactive hydrazone, which may result in functional Vitamin B6 (Aminolean) deficiency Levodopa: Concomitant use of levodopa and Vitamin B6 (Aminolean) in doses of 5 milligrams or more daily may reverse the therapeutic effects of levodopa. Vitamin B6 (Aminolean) does not reverse the therapeutic effects of levodopa if levodopa is taken concurrently with the levodopa decarboxylase inhibitor carbidopa. Levodopa is typically administered as a combination product with carbidopa

Oral contraceptives: The use of oral contraceptives may increase Vitamin B6 (Aminolean) requirements. This was more the case with the older oral contraceptive agents with high-dose estrogen/progestin. It appears to be less the case with the newer low-dose estrogen/progestin products Penicillamine: Penicillamine may react with pyridoxal 5-phosphate to form a metabolically inactive thiazolidine, which may result in a functional Vitamin B6 (Aminolean) deficiency Phenelzine: Phenelzine may react with pyridoxal 5-phosphate to yield a metabolically inactive hydrazone compound Phenobarbital: High doses of Vitamin B6 (Aminolean) may lower plasma levels of phenobarbital Phenytoin: High doses of Vitamin B6 (Aminolean) may lower plasma levels of phenytoin Theophylline: Theophylline may react with pyridoxal 5-phosphate leading to low plasma levels of the coenzyme. This may increase the risk of theophylline-induced seizures Valproic acid: Chronic use of valproic acid may result in a significant decrease in plasma pyridoxal 5-phosphate levels.

See also:
What are the possible side effects of Arginine (Aminolean)?

Adverse reactions associated with 1670 infusions in premarketing studies were as follows:

Non-specific side effects consisting of nausea, vomiting, headache, flushing, numbness and local venous irritation were reported in approximately 3% of the patients.

One patient had an allergic reaction which was manifested as a confluent macular rash with reddening and swelling of the hands and face. The rash subsided rapidly after the infusion was terminated and 50 mg of diphenhydramine were administered. One patient had an apparent decrease in platelet count from 150,000 to 60,000. One patient with a history of acrocyanosis had an exacerbation of this condition following infusion of Arginine (Aminolean).

Post Marketing Experience

The following adverse events have been reported during post-marketing use: extravasation leading to burn-like reaction and/or skin necrosis requiring surgical intervention, hypersensitivity reactions including anaphylaxis, and hematuria that in some cases occurred 1–2 days after an Arginine (Aminolean) administration. Because these adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Abdominal discomfort, nausea, vomiting and diarrhea have been reported occasionally. These symptoms may disappear by administering the product right dose after meals.

See also:
What are the possible side effects of Calcium Chloride (Aminolean)?

Adverse Reactions

Frequency not defined. IV:

Cardiovascular (following rapid IV injection): Bradycardia, cardiac arrest, cardiac arrhythmia, hypotension, syncope, vasodilation

Central nervous system: Feeling abnormal (sense of oppression; with rapid IV injection), tingling sensation (with rapid IV injection)

Endocrine & metabolic: Hot flash (with rapid IV injection), hypercalcemia

Gastrointestinal: Dysgeusia (chalky taste), gastrointestinal irritation, increased serum amylase

Local: Local tissue necrosis (following extravasation)

Renal: Nephrolithiasis

Postmarketing and/or case reports: Cutaneous calcification

See also:
What are the possible side effects of Dextrose (Aminolean)?

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

Too rapid infusion of hypertonic solutions may cause local pain and venous irritation. Rate of administration should be adjusted according to tolerance. Use of the largest peripheral vein and a small bore needle is recommended.

Dextrose (Aminolean) may be administered at a rate of 0.5 g/kg/hour without producing glycosuria. Hyperglycemia and glycosuria may be a function of rate of administration or metabolic insufficiency. Appropriate therapy may include slowing of the infusion rate and administration of insulin.

Too rapid administration of hypertonic Dextrose (Aminolean) solutions may result in hyperosmolar syndrome with signs of mental confusion and/or loss of consciousness. If undetected and untreated, this can lead to osmotic dehydration, hyperosmolar coma and death.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

Adverse reactions may include fluid and electrolyte disorders such as acidosis, electrolyte loss, marked diuresis, urinary retention, edema and dehydration; cardiovascular/pulmonary disorders such as pulmonary congestion, hypotension, tachycardia, angina-like pain and thrombophlebitis; other possible reactions include visual disturbances, convulsions, nausea, vomiting, diarrhea, vertigo and urticaria.

Literature includes reports on hyponatremia, hyperammonemia, transient blindness, coma (immediate or delayed), and digitalis toxicity in digitalized patients.

If an adverse reaction occurs, discontinue the irrigant and reevaluate the clinical status of the patient.

water weight gain, edema, increase in BUN, and dilutional hyponatremia. Asterixis was reported to have worsened in one patient during infusion of this medicine.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential.

Phosphorus deficiency may lead to impaired tissue oxygenation and acute hemolytic anemia. Relative to calcium, excessive phosphorus intake can precipitate hypocalcemia with cramps, tetany and muscular hyperexcitability.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

water weight gain, edema, increase in BUN, and dilutional hyponatremia. Asterixis was reported to have worsened in one patient during infusion of this medicine.

Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.

Symptoms may result from an excess or deficit of one or more of the ions present in the solution; therefore, frequent monitoring of electrolyte levels is essential.

Phosphorus deficiency may lead to impaired tissue oxygenation and acute hemolytic anemia. Relative to calcium, excessive phosphorus intake can precipitate hypocalcemia with cramps, tetany and muscular hyperexcitability.

If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.

See also:
What are the possible side effects of Magnesium Sulfate (Aminolean)?

Applies to Magnesium Sulfate (Aminolean): crystal, ointment, powder, powder for solution, powder for suspension

In addition to its needed effects, some unwanted effects may be caused by Magnesium Sulfate (Aminolean) (the active ingredient contained in Magnesium Sulfate (Aminolean)). In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking Magnesium Sulfate (Aminolean):

Incidence not known:

• Confusion
• dizziness or lightheadedness
• fast, slow, or irregular heartbeat
• low blood pressure
• muscle weakness
• skin infection after soaking
• sleepiness

Minor Side Effects

Some of the side effects that can occur with Magnesium Sulfate (Aminolean) may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Incidence not known:

• Diarrhea
• skin irritation after soaking

See also:
What are the possible side effects of Potassium Chloride (Aminolean)?

One of the most severe adverse effects is hyperkalemia. Gastrointestinal bleeding and ulceration have been reported in patients treated with Potassium Chloride (Aminolean) (Potassium Chloride (Aminolean) extended-release) ® Extencaps®. In addition to gastrointestinal bleeding and ulceration, perforation and obstruction have been reported in patients treated with other solid KCl dosage forms, and may occur with Potassium Chloride (Aminolean) (Potassium Chloride (Aminolean) extended-release) ® Extencaps®.

The most common adverse reactions to the oral potassium salts are nausea, vomiting, flatulence, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by taking the dose with meals, or reducing the amount taken at one time. Skin rash has been reported rarely with potassium preparations.

See also:
What are the possible side effects of Sodium Acetate (Aminolean)?

Adverse Reactions

1% to 10%:

Cardiovascular: Localized phlebitis, thrombosis

Endocrine & metabolic: Electrolyte disturbance (dilution of serum electrolytes), hypernatremia, hypervolemia, hypocalcemia, hypokalemia, metabolic alkalosis, water intoxication

Gastrointestinal: Abdominal distention, flatulence

Respiratory: Pulmonary edema

See also:
What are the possible side effects of Tryptophan (Aminolean)?

Nausea (take after food to minimise nausea), headache, lightheadedness, drowsiness, eosinophilia-myalgia syndrome.

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Although not all side effects are known, Tyrosine (Aminolean) is thought to be likely safe in most adults when taken for up to 3 months.

Common side effects may include:

• nausea, heartburn;

• headache;

• joint pain; or

• feeling tired.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

See also:
What are the possible side effects of Vitamin B1 (Aminolean)?

Applies to thiamine: capsule, solution, tablet, tablet enteric coated

As well as its needed effects, thiamine (the active ingredient contained in Vitamin B1 (Aminolean)) may cause unwanted side effects that require medical attention.

Major Side Effects

If any of the following side effects occur while taking thiamine, check with your doctor immediately:

Rare - Soon after receiving injection only

• Coughing
• difficulty in swallowing
• hives
• itching of skin
• swelling of face, lips, or eyelids
• wheezing or difficulty in breathing

See also:
What are the possible side effects of Vitamin B12 (Aminolean)?

Applies to cyanocobalamin: intramuscular solution

Other dosage forms:

• nasal gel/jelly, nasal spray

As well as its needed effects, cyanocobalamin (the active ingredient contained in Vitamin B12 (Aminolean)) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking cyanocobalamin, check with your doctor or nurse immediately:

Incidence not known:

• Abdominal or stomach pain
• bleeding from the gums or nose
• blue lips and fingernails
• chest pain
• cough
• coughing that sometimes produces a pink frothy sputum
• decreased urine output
• difficult, fast, noisy breathing, sometimes with wheezing
• difficulty with swallowing
• dilated neck veins
• dizziness
• extreme fatigue
• eye pain
• fast heartbeat
• headache
• hives, itching, or skin rash
• increased sweating
• irregular breathing
• irregular heartbeat
• pale skin
• puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
• ringing in the ears
• swelling of the face, fingers, feet, or lower legs
• tightness in the chest
• unusual tiredness or weakness
• weight gain

Minor Side Effects

Some cyanocobalamin side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

Incidence not known:

• Diarrhea
• skin rash with a general disease

Allergic sensitization has been reported rarely following oral and parenteral administration of Folic Acid.

At recommended doses, nicotinamide is expected to be well tolerated. Gastrointestinal distress such as nausea or vomiting have been associated with the administration of nicotinamide or zinc at doses greater than the recommended dose of nicotinamide

Nicotinamide: Dizziness, headache, hyperglycemia, nausea, vomiting, diarrhea, elevations in liver function tests, hepatotoxicity, blurred vision, flushing, rash.

No serious side effects have been reported, even at intakes of up to 10,000 mg (10 grams) per day. Very large amounts of pantothenic acid (several grams per day) can cause diarrhea.

Pantothenic acid works together with Vitamin B5 (Aminolean), vitamin B2, and Vitamin B5 (Aminolean) to help make the fuel our bodies run on—ATP.

There is one report of a 76-year-old woman who developed a life-threatening condition (eosinophilic pleuropericardial effusion) while taking 300 mg of pantothenic acid per day and 10 mg of biotin per day.2 However, it is not clear whether the vitamins caused the problem.

See also:
What are the possible side effects of Vitamin B6 (Aminolean)?

Applies to pyridoxine: capsule, injectable, solution, tablet, tablet enteric coated, tablet extended release

As well as its needed effects, pyridoxine (the active ingredient contained in Vitamin B6 (Aminolean)) may cause unwanted side effects that require medical attention.

Severity: Moderate

If any of the following side effects occur while taking pyridoxine, check with your doctor or nurse as soon as possible:

With large doses

• Clumsiness
• numbness of hands or feet